Bayer lauds China's impact on clinical development, research

China's emphasis on innovation in recent years has led to more opportunities for global clinical development and research programs to be carried out in the country, which has benefitted its people, said the executive of a leading German pharmaceutical company.

Dieter Weinand, president of Bayer AG's pharmaceuticals division and a member of the company's management board, said: "The Chinese government is taking the right steps in assuring that new medicines can be approved in China faster, by allowing full studies conducted in other countries to be utilized and updated in China."

He said the company previously had to set up a separate program for China, which meant it took much longer for new medicines to reach the Chinese market.